Skip Navigation

Japanese Journal of Clinical Oncology 2004 34(9):505-509; doi:10.1093/jjco/hyh093
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kikuchi, J.
Right arrow Articles by Nishimura, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kikuchi, J.
Right arrow Articles by Nishimura, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2004 Foundation for Promotion of Cancer Research

Phase I Trial of Carboplatin and Weekly Paclitaxel in Patients With Advanced Non-small-cell Lung Cancer

Junko Kikuchi1, Koichi Yamazaki1, Ichiro Kinoshita2, Hajime Asahina1, Mikado Imura1, Eiki Kikuchi1, Jun Konishi1, Naofumi Shinagawa1, Hiromitsu Oki3, Hirotoshi Dosaka-Akita2 and Masaharu Nishimura1

1 First Department of Medicine, Hokkaido University School of Medicine, Sapporo, 2 Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo and 3 Department of Pharmacy, Hokkaido University Hospital, Sapporo, Japan

For reprints and all correspondence: Koichi Yamazaki, First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kitaku, Sapporo 060-8638, Japan. E-mail: kyamazak{at}med.hokudai.ac.jp

Received April 15, 2004; accepted June 20, 2004

Objective: This study was designed to determine the maximum tolerated dose of paclitaxel administered weekly in combination with carboplatin and to assess its dose limiting toxicity and preliminary activity in patients with previously untreated, advanced non-small-cell lung cancer.

Methods: Carboplatin was administered at a fixed dose that maintained an area under the curve of 6. Paclitaxel was given over 1 h once a week for 3 weeks starting at 60 mg/m2 and escalated in 10 mg/m2 increments.

Results: Twenty-one patients were treated with six dose levels (60, 70, 80, 90, 100, 110 mg/m2) of paclitaxel. The dose limiting toxicity was infection and the maximum tolerated dose was 110 mg/m2. Nine of 21 (42.9%) patients demonstrated a therapeutic response.

Conclusion: Weekly paclitaxel and carboplatin were well tolerated. Based on our results, 100 mg/m2 of paclitaxel for 3 weeks of a 4-week cycle, in combination with carboplatin, was recommended for a phase II study.

Key Words: carboplatin • non-small-cell lung cancer • paclitaxel • phase I study


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
K. Naoki, H. Kunikane, T. Fujii, S. Tsujimura, N. Hida, H. Okamoto, and K. Watanabe
Dose-escalating and Pharmacokinetic Study of a Weekly Combination of Paclitaxel and Carboplatin for Inoperable Non-small Cell Lung Cancer: JCOG 9910-DI
Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 569 - 575.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.